ANI Pharmaceuticals is a pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include, among others: Arimidex, which is used for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer; Erythromycin Ethylsuccinate, which is used to treat infections caused by susceptible strains of designated organisms for selected diseases; Diphenoxylate Hydrochloride and Atropine Sulfate, which is used as an adjunctive therapy in the management of diarrhea; and Etodolac, which is used to treat mild to moderate pain caused by osteoarthritis and rheumatoid arthritis. The ANIP stock yearly return is shown above.
The yearly return on the ANIP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANIP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|